<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31284522</article-id>
<article-id pub-id-type="pmc">6651320</article-id>
<article-id pub-id-type="doi">10.3390/ijms20133317</article-id>
<article-id pub-id-type="publisher-id">ijms-20-03317</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Loss of Mevalonate/Cholesterol Homeostasis in the Brain: A Focus on Autism Spectrum Disorder and Rett Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Segatto</surname>
<given-names>Marco</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-03317">1</xref>
<xref ref-type="author-notes" rid="fn1-ijms-20-03317">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tonini</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-03317">2</xref>
<xref ref-type="author-notes" rid="fn1-ijms-20-03317">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pfrieger</surname>
<given-names>Frank W.</given-names>
</name>
<xref ref-type="aff" rid="af3-ijms-20-03317">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trezza</surname>
<given-names>Viviana</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-03317">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2511-6168</contrib-id>
<name>
<surname>Pallottini</surname>
<given-names>Valentina</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-03317">2</xref>
<xref ref-type="corresp" rid="c1-ijms-20-03317">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-20-03317"><label>1</label>Department of Biosciences and Territory, University of Molise, Contrada Fonte Lappone, 86090 Pesche (IS), Italy</aff>
<aff id="af2-ijms-20-03317"><label>2</label>Department of Science, University Roma Tre, Viale Marconi, 446, 00146 Rome, Italy</aff>
<aff id="af3-ijms-20-03317"><label>3</label>Institute of Cellular and Integrative Neurosciences (INCI) CNRS UPR 3212, Université de Strasbourg, 5, rue Blaise Pascal, 67084 Strasbourg Cedex, France</aff>
<author-notes>
<corresp id="c1-ijms-20-03317"><label>*</label>Correspondence: <email>valentina.pallottini@uniroma3.it</email></corresp>
<fn id="fn1-ijms-20-03317">
<label>†</label>
<p>These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>7</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>13</issue>
<elocation-id>3317</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The mevalonate (MVA)/cholesterol pathway is crucial for central nervous system (CNS) development and function and consequently, any dysfunction of this fundamental metabolic pathway is likely to provoke pathologic changes in the brain. Mutations in genes directly involved in MVA/cholesterol metabolism cause a range of diseases, many of which present neurologic and psychiatric symptoms. This raises the question whether other diseases presenting similar symptoms are related albeit indirectly to the MVA/cholesterol pathway. Here, we summarized the current literature suggesting links between MVA/cholesterol dysregulation and specific diseases, namely autism spectrum disorder and Rett syndrome.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorder</kwd>
<kwd>brain</kwd>
<kwd>cholesterol</kwd>
<kwd>mevalonate pathway</kwd>
<kwd>Rett syndrome</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-20-03317" sec-type="intro">
<title>1. Introduction</title>
<sec>
<title>Cholesterol Metabolism in the Brain</title>
<p>The brain contains 23% of the cholesterol in the human body although it represents only the 2% of the total body weight [<xref ref-type="bibr" rid="B1-ijms-20-03317">1</xref>] indicating the importance of this molecule for the central nervous system (CNS). Cholesterol is a key constituent of myelin sheaths and neuronal membranes [<xref ref-type="bibr" rid="B2-ijms-20-03317">2</xref>]. Specifically, cholesterol is a main component of synaptic vesicles: their formation, shape, and release are critically dependent on this lipid. Moreover cholesterol plays a role in the proper structural organization of postsynaptic densities [<xref ref-type="bibr" rid="B3-ijms-20-03317">3</xref>]. Cholesterol is not homogeneously dispersed within membranes: it is more abundant in the cytosolic part of the plasma membrane [<xref ref-type="bibr" rid="B4-ijms-20-03317">4</xref>] and it is enriched in dynamic structures called “lipid rafts” that play important roles in signal transduction across membranes [<xref ref-type="bibr" rid="B5-ijms-20-03317">5</xref>]. In neurons, lipid rafts have been observed at synapses, where they could contribute to pre- and postsynaptic function [<xref ref-type="bibr" rid="B6-ijms-20-03317">6</xref>,<xref ref-type="bibr" rid="B7-ijms-20-03317">7</xref>,<xref ref-type="bibr" rid="B8-ijms-20-03317">8</xref>,<xref ref-type="bibr" rid="B9-ijms-20-03317">9</xref>,<xref ref-type="bibr" rid="B10-ijms-20-03317">10</xref>]. Thus, an imbalance in cholesterol homeostasis both at the presynaptic and postsynaptic side is likely to impact neurotransmission, and induce the loss of synapses and dendritic spines [<xref ref-type="bibr" rid="B11-ijms-20-03317">11</xref>,<xref ref-type="bibr" rid="B12-ijms-20-03317">12</xref>]. Remarkably, cholesterol metabolism in the brain is completely separated from the rest of the body since lipoproteins containing cholesterol cannot cross the blood brain barrier (BBB). Cholesterol present in the CNS must be synthesized in situ [<xref ref-type="bibr" rid="B13-ijms-20-03317">13</xref>]. The synthesis of this lipid is assured by the so-called mevalonate (MVA) pathway [<xref ref-type="bibr" rid="B14-ijms-20-03317">14</xref>] that starts from acetate and comprises a series of ~30 enzymatic reactions. A key enzyme of this pathway is the 3-hydroxy-3-methylglutaryl Coenzyme A reductase (HMGCR), an integral membrane protein in the endoplasmic reticulum (ER) that reduces the 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) to mevalonic acid (MVA). The membrane embedded portion of HMGCR contains a sterol-sensing domain (SSD) with five helices that is shared by several proteins involved in cholesterol homeostasis [<xref ref-type="bibr" rid="B15-ijms-20-03317">15</xref>]. The SSD of HMGCR is crucial for the regulated degradation of the enzyme by the proteasome [<xref ref-type="bibr" rid="B16-ijms-20-03317">16</xref>]. Importantly, MVA is the precursor of compounds other than cholesterol that are involved in diverse cellular processes such as transcription (isopentenyl tRNAs), protein <italic>N</italic>-glycosylation (dolichol phosphate), protein prenylation (farnesylation and geranylgeranylation), and mitochondrial electron transport (ubiquinone) (<xref ref-type="fig" rid="ijms-20-03317-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B17-ijms-20-03317">17</xref>].</p>
<p>Several studies suggest that neurons produce cholesterol during prenatal life and depend on cholesterol synthesis by astrocytes after birth [<xref ref-type="bibr" rid="B12-ijms-20-03317">12</xref>,<xref ref-type="bibr" rid="B13-ijms-20-03317">13</xref>]. In the mouse CNS, cholesterol is synthesized at a rate of 0.26 mg/day during the first week of life. In adult animals, the synthesis exceeds the need and surplus cholesterol is excreted to plasma a rate of about 0.023 mg/day [<xref ref-type="bibr" rid="B18-ijms-20-03317">18</xref>]. To this end, cholesterol is transformed by cholesterol 24-hydroxylase (CYP46A1) into 24-<italic>S</italic> hydroxycholesterol (24-<italic>S</italic>-OH), which is able to cross the BBB. The 24-<italic>S</italic>-OH is continually produced in the brain, mainly by neurons, and excreted into the bloodstream both in rodents and in humans [<xref ref-type="bibr" rid="B18-ijms-20-03317">18</xref>]. This seemed to be the main mechanism to remove cholesterol from CNS [<xref ref-type="bibr" rid="B19-ijms-20-03317">19</xref>,<xref ref-type="bibr" rid="B20-ijms-20-03317">20</xref>], but data obtained by gas chromatography (GC)-MS have shown that the cholesterol metabolites 5α-hydroxy-6-oxocholesterol (3β,5α-dihydroxycholestan-6-one), 7β-hydroxycholesterol and 7-oxocholesterol, generally considered to be formed through reactive oxygen species, are similarly exported from brain at rates of about 0.1, 2 and 2 mg/24 h, respectively [<xref ref-type="bibr" rid="B21-ijms-20-03317">21</xref>]. Brain cholesterol metabolism, in particular the MVA pathway, display region-, age-, and sex-specific differences. It has been shown that brain regions differ with respect to the activity and the content of proteins mediating cholesterol homeostasis. In particular, our research group demonstrated that cholesterol biosynthesis and uptake are differently modulated in different brain regions of adult male rats. The HMGCR activity is very low in the brain stem, and high in hippocampus, brain cortex and cerebellum. These regional differences depend on sex- and age-specific metabolic regulation [<xref ref-type="bibr" rid="B22-ijms-20-03317">22</xref>,<xref ref-type="bibr" rid="B23-ijms-20-03317">23</xref>].</p>
</sec>
</sec>
<sec id="sec2-ijms-20-03317">
<title>2. Diseases with Direct Links to Cholesterol Homeostasis</title>
<p>The eminent importance of the cholesterol/MVA pathway for brain development and function is illustrated by hereditary albeit rare diseases that affect genes mediating cholesterol homeostasis (<xref ref-type="table" rid="ijms-20-03317-t001">Table 1</xref>).</p>
<p>The autosomal recessive Smith–Lemli–Opitz syndrome (SLOS, OMIM 270400) is caused by mutations in the gene encoding 7-dehydrocholesterol reductase (DHCR7). This enzyme catalyzes the last step in the Kandutsch–Russell branch of the cholesterol/MVA synthesis (<xref ref-type="fig" rid="ijms-20-03317-f001">Figure 1</xref>). The most severe mutations of this gene cause fetal or newborn death, while less severe variants cause developmental defects in specific organs such as facial and cranial malformations, hypospadia or complete gonadal absence [<xref ref-type="bibr" rid="B24-ijms-20-03317">24</xref>]. Some SLOS patients show intellectual disability, perturbed sleep, delayed acquisition of motor and language skills as well as impaired social interactions. The mechanisms causing this range of symptoms are not well understood. Evidently, dysfunction of DHCR7 will lead to lower cholesterol levels. In fact, the most severely affected patients present low cholesterol content down to 2% of the normal levels [<xref ref-type="bibr" rid="B25-ijms-20-03317">25</xref>]. Low cholesterol levels may impair sonic hedgehog signaling and cause the striking developmental malformations. Activity of this signaling factor and its distribution are regulated by posttranslational attachment of cholesterol to its amino terminus [<xref ref-type="bibr" rid="B26-ijms-20-03317">26</xref>,<xref ref-type="bibr" rid="B27-ijms-20-03317">27</xref>,<xref ref-type="bibr" rid="B28-ijms-20-03317">28</xref>].</p>
<p>SLOS patients with neurologic symptoms can present normal amount of plasma cholesterol probably due to dietary intake. Nevertheless, diet-derived cholesterol cannot cross the BBB and cannot compensate the low cholesterol level in the brain [<xref ref-type="bibr" rid="B3-ijms-20-03317">3</xref>,<xref ref-type="bibr" rid="B24-ijms-20-03317">24</xref>]. It is also possible that neurologic symptoms are caused by accumulation of 7-dehydrocholesterol (7-DHC), a DHCR7 substrate, or its oxidized metabolites [<xref ref-type="bibr" rid="B29-ijms-20-03317">29</xref>]. It has been demonstrated that the accumulation of 7-DHC in fibroblasts impairs intracellular cholesterol transport and increases the degradation rate of HMGCR, contributing to a reduced sterol synthesis in SLOS patients [<xref ref-type="bibr" rid="B30-ijms-20-03317">30</xref>]. The therapeutic goal for the treatment of SLOS should be to increase cholesterol content and to decrease the accumulation of the cholesterol precursors such as 7-DHC. Cholesterol supplementation in SLOS patients showed unclear results. Some reports described an improvement in alertness, attention, mood and affection, whereas others demonstrated no ability to restore any developmental acquired skills [<xref ref-type="bibr" rid="B31-ijms-20-03317">31</xref>,<xref ref-type="bibr" rid="B32-ijms-20-03317">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-03317">33</xref>]. Potentially toxic cholesterol precursors may be lowered by treatment with HMGCR inhibitors, the statins, although this treatment may appear counterintuitive and paradoxal for syndrome caused by defect in cholesterol synthesis. Treatment of SLOS subjects with simvastatin and cholesterol demonstrated irritability and self-injury, improved appetite and sleeping patterns, while no change was detectable in the IQ score [<xref ref-type="bibr" rid="B34-ijms-20-03317">34</xref>]. A recent study showed that treatment of a SLOS preclinical rodent model with cholesterol plus suitable antioxidants completely prevented the retinal degeneration [<xref ref-type="bibr" rid="B35-ijms-20-03317">35</xref>] providing some hopes to SLOS patients.</p>
<p>A second genetic disorder that is directly linked to cholesterol is Niemann-Pick type C disease (NPC, OMIM 257220). The pathology is characterized by intracellular accumulation of unesterified cholesterol and glycolipids in the endosomal/lysosomal system [<xref ref-type="bibr" rid="B36-ijms-20-03317">36</xref>]. Approximately 95% and 5% of cases are caused by mutations in the ubiquitously expressed Niemann-Pick type C 1 (NPC1) and NPC2 gene, which encode for a large membrane glycoprotein in late endosomes, and for a small soluble lysosomal protein, respectively. Structural analyses indicate that both molecules cooperatively mediate the exit of unesterified cholesterol from the endosomal/lysosomal system. NPC patients present with highly variable age of onset, neurovisceral symptoms, and life-span ranging from a few years to decades of life. A hallmark present in nearly all patients is supranuclear gaze palsy, other clinical manifestations are cerebellar ataxia, movement disorders, epileptic seizure, dysartria, cataplexy, dysphagia, vertical supranuclear ophthalmoplegia, dystonia, and progressive memory deficits as well as dementia [<xref ref-type="bibr" rid="B37-ijms-20-03317">37</xref>]. Interestingly, patients with the same mutation show very different pathological symptoms [<xref ref-type="bibr" rid="B36-ijms-20-03317">36</xref>,<xref ref-type="bibr" rid="B38-ijms-20-03317">38</xref>]. The large symptomatic spectrum suggests the presence of disease modifiers that are still largely unknown. At present, there is no curative treatment for this disease, and reduction of glycolipids by <italic>N</italic>-butyl-deoxynojirimycin (Miglustat) is the only therapeutic option in the EU [<xref ref-type="bibr" rid="B39-ijms-20-03317">39</xref>]. Recent data suggest a new therapeutic drug candidate, β-cyclodextrin [<xref ref-type="bibr" rid="B40-ijms-20-03317">40</xref>], which may resolubilize cholesterol within cells and induce the release of cholesterol-rich membrane inclusions [<xref ref-type="bibr" rid="B41-ijms-20-03317">41</xref>].</p>
<p>A third autosomal recessive disease with direct links to cholesterol is desmosterolosis (OMIM 602398), which is caused by mutations in the 24-dehydrocholesterol reductase (DHCR24) (<xref ref-type="fig" rid="ijms-20-03317-f001">Figure 1</xref>). This enzyme catalyzes the reduction of desmosterol to cholesterol, a crucial step in the Bloch branch of cholesterol synthesis (<xref ref-type="fig" rid="ijms-20-03317-f001">Figure 1</xref>) [<xref ref-type="bibr" rid="B42-ijms-20-03317">42</xref>]. Patients with desmosterolosis present microcephalia, hydrocephalia, ventricular enlargement, defects in the corpus callosum, and thinning of white matter and seizures. As for SLOS, the symptoms of this disease may be attributed to reduced cholesterol levels or to accumulation of a precursor, in this case desmosterol. There is currently no therapy for this disease.</p>
</sec>
<sec id="sec3-ijms-20-03317">
<title>3. Neurodegenerative Diseases with Suspected Links to Cholesterol Metabolism</title>
<p>Several diseases including Alzheimer, Huntington, and Parkinson diseases are thought to involve changes in cholesterol metabolism although a direct link cannot be established [<xref ref-type="bibr" rid="B14-ijms-20-03317">14</xref>] (<xref ref-type="table" rid="ijms-20-03317-t001">Table 1</xref>). Alzheimer’s disease (AD, OMIM 104300) is a neurodegenerative disorder characterized by progressive behavioral and mood alterations including memory loss. AD is considered a proteopathy due to the intracellular and extracellular accumulation of neurofibrillary tangles made of tau and of plaques containing amyloid beta, respectively in the CNS of patients. Cholesterol has been implied in the production and clearance of beta amyloid [<xref ref-type="bibr" rid="B24-ijms-20-03317">24</xref>]. Moreover, several proteins involved in cholesterol homeostasis have been associated with AD. A specific variant of the gene encoding for apolipoprotein E, which transports cholesterol in the brain, is one of the best established risk factors for late onset/sporadic AD [<xref ref-type="bibr" rid="B43-ijms-20-03317">43</xref>]. Two polymorphisms of <italic>CYP46</italic> have been related to AD [<xref ref-type="bibr" rid="B44-ijms-20-03317">44</xref>,<xref ref-type="bibr" rid="B45-ijms-20-03317">45</xref>]. Finally, AD-related polymorphisms were detected for ATP binding cassette 1 protein (ABCA1), a protein that transfers cholesterol from cells to apolipoprotein A1-containing lipoproteins [<xref ref-type="bibr" rid="B46-ijms-20-03317">46</xref>]. Several clinical trials using statins have been started, for the moment, the results seem to be debated [<xref ref-type="bibr" rid="B47-ijms-20-03317">47</xref>]. Recently, however, a direct interaction between statins and amyloid beta has been demonstrated in silico [<xref ref-type="bibr" rid="B48-ijms-20-03317">48</xref>].</p>
<p>Huntington’s disease (HD, OMIM 143100) is an autosomal-dominant disorder characterized by adult onset, progressive motor dysfunction, dementia, cognitive decline and psychiatric disturbances, which leads to death, approximately 15–20 years after disease onset. CAG repeats in the gene encoding for the huntingtin protein (HTT) are the cause of this disease. HTT plays a role in vesicle transport and cytoskeletal anchoring in clathrin-mediated endocytosis, neuronal transport and postsynaptic signaling; also, it protects neuronal cells from apoptotic stress and therefore may have a central function in cell survival [<xref ref-type="bibr" rid="B49-ijms-20-03317">49</xref>]. However, it remains unclear whether and how mutant huntingtin causes neuronal degeneration and death. It has been demonstrated in vitro that mutant HTT represses genes involved in cholesterol metabolism [<xref ref-type="bibr" rid="B50-ijms-20-03317">50</xref>] possibly due to a lower transcriptional activity of the Sterol Regulatory Element Binding Protein 2 (SREBP2). This transcription factor regulates a cassette of genes involved in cholesterol homeostasis [<xref ref-type="bibr" rid="B3-ijms-20-03317">3</xref>]. Somewhat conflicting findings in HD mouse models gave rise to contrasting hypothesis regarding the HD-dependent cholesterol alteration: the first suggests that neurons suffer from a lack of cholesterol due to impaired biosynthesis [<xref ref-type="bibr" rid="B51-ijms-20-03317">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-03317">52</xref>]. The alternative hypothesis assumes an accumulation of cholesterol in membranes causing a decreased synthesis and a paralleled reduction in the production of 24-<italic>S</italic>-OH by CYP46A [<xref ref-type="bibr" rid="B20-ijms-20-03317">20</xref>]. Accordingly, restoring normal levels of cholesterol is preclinically explored using administration of cholesterol-laden nanoparticles [<xref ref-type="bibr" rid="B53-ijms-20-03317">53</xref>] and the increase of CYP46A levels using gene therapy [<xref ref-type="bibr" rid="B20-ijms-20-03317">20</xref>], respectively.</p>
<p>Several studies suggest possible correlations between mood disorders and altered cholesterol levels, both in brain and blood [<xref ref-type="bibr" rid="B82-ijms-20-03317">82</xref>]. Statins induce side effects such as irritability and violence [<xref ref-type="bibr" rid="B82-ijms-20-03317">82</xref>,<xref ref-type="bibr" rid="B83-ijms-20-03317">83</xref>] and a case study showed complete reversal of these changes upon suspension of drug treatment [<xref ref-type="bibr" rid="B84-ijms-20-03317">84</xref>]. Other studies suggest a correlation between cholesterolemia and psychiatric alterations such as suicide [<xref ref-type="bibr" rid="B85-ijms-20-03317">85</xref>,<xref ref-type="bibr" rid="B86-ijms-20-03317">86</xref>,<xref ref-type="bibr" rid="B87-ijms-20-03317">87</xref>] and depression, the latter of which may be sex-dependent [<xref ref-type="bibr" rid="B88-ijms-20-03317">88</xref>,<xref ref-type="bibr" rid="B89-ijms-20-03317">89</xref>,<xref ref-type="bibr" rid="B90-ijms-20-03317">90</xref>]. An association between schizophrenia and plasma cholesterol level has been described since 1952 [<xref ref-type="bibr" rid="B90-ijms-20-03317">90</xref>,<xref ref-type="bibr" rid="B91-ijms-20-03317">91</xref>,<xref ref-type="bibr" rid="B92-ijms-20-03317">92</xref>,<xref ref-type="bibr" rid="B93-ijms-20-03317">93</xref>]. However, the studies correlating cholesterolemia and behavior have to be carefully considered since blood levels of cholesterol are completely independent from the brain and correlations cannot establish causal relations.</p>
</sec>
<sec id="sec4-ijms-20-03317">
<title>4. Autism Spectrum Disorder</title>
<p>A connection between autism spectrum disorder (ASD) and mevalonate/cholesterol metabolism has been suggested recently. ASD refers to a range of developmental psychiatric disorders characterized by deficits in social communication and interactions, restricted interests and repetitive behaviors that appear during the first two years of life [<xref ref-type="bibr" rid="B58-ijms-20-03317">58</xref>]. </p>
<p>In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders [<xref ref-type="bibr" rid="B59-ijms-20-03317">59</xref>], the traditional three symptom domains of ASD (i.e., social impairment, communication deficit, and atypical/repetitive behaviors) have been reduced to two, by combining the social and communication symptoms into one single diagnostic criterion of social-communicative deficits. The deficit in the socio-communicative domain appear already at infancy: babies with ASD may show lack or weak response to the parents’ voice, tend to not use their voice to attract attention to themselves, to express emotions or establish contact, and may be unresponsive to social stimuli, avoiding interaction with others. As the children get older, withdrawal from social interactions, indifference to social activities and deficits in social communication become more evident, while the language appear highly impoverished [<xref ref-type="bibr" rid="B58-ijms-20-03317">58</xref>,<xref ref-type="bibr" rid="B94-ijms-20-03317">94</xref>]. The second symptom domain of ASD includes restricted, repetitive patterns of behaviors, interests or activities [<xref ref-type="bibr" rid="B59-ijms-20-03317">59</xref>]. </p>
<p>No specific drug treatment is currently available for ASD. In line with the multitude of symptoms displayed by ASD patients, it is not surprising that different etiological components are involved in the pathogenesis of the disease, including genetic and environmental factors [<xref ref-type="bibr" rid="B95-ijms-20-03317">95</xref>]. The concordance rate, ranging from 60–95% in monozygotic twins to 2–6% in dizygotic twins, indicates that genetic factors play a key role. Indeed, several single gene mutations, polymorphisms and copy number variations have been associated with ASD. However, the fact that the concordance is less than 100% in monozygotic twins indicates that environmental and epigenetic factors are also involved [<xref ref-type="bibr" rid="B96-ijms-20-03317">96</xref>]. Indeed, several prenatal and perinatal risk factors have been identified, including exposure to intrauterine infections, maternal treatment with drugs such as valproic acid and thalidomide, and exposure to toxicants such as organophosphate insecticides or heavy metals [<xref ref-type="bibr" rid="B96-ijms-20-03317">96</xref>]. For this reason, ASD is by now considered as a multifactorial disease [<xref ref-type="bibr" rid="B95-ijms-20-03317">95</xref>,<xref ref-type="bibr" rid="B96-ijms-20-03317">96</xref>,<xref ref-type="bibr" rid="B97-ijms-20-03317">97</xref>]. A recent study reveals age- and region-dependent alterations of proteins involved in cholesterol metabolism in the brains of a well-established rat model [<xref ref-type="bibr" rid="B54-ijms-20-03317">54</xref>] based on prenatal exposure to valproic acid (VPA) [<xref ref-type="bibr" rid="B55-ijms-20-03317">55</xref>]. This includes changes in the activation state of HMGCR and in the levels of several receptors mediating cholesterol uptake and release. Adolescent VPA-exposed rats showed a strong increase of membrane-attached geranylgeranylated RhoA in the cerebellum, a reduced level of the farnesylated Ras in the Nucleus Accumbens and a reduction of oligodendrocytes were observed [<xref ref-type="bibr" rid="B55-ijms-20-03317">55</xref>]. Intriguingly, some of these changes were sex-dependent [<xref ref-type="bibr" rid="B56-ijms-20-03317">56</xref>,<xref ref-type="bibr" rid="B57-ijms-20-03317">57</xref>]. The sex-dependency is in agreement with the dimorphic onset of ASD, which is more frequent in boys than girls with a ratio of 3:1 [<xref ref-type="bibr" rid="B98-ijms-20-03317">98</xref>], and with the differences in cholesterol homeostasis between human males and females [<xref ref-type="bibr" rid="B23-ijms-20-03317">23</xref>,<xref ref-type="bibr" rid="B99-ijms-20-03317">99</xref>]. A prominent sex-dependent change in the brains of VPA-exposed rats concerns LRP1 (LDLR related protein 1) [<xref ref-type="bibr" rid="B55-ijms-20-03317">55</xref>,<xref ref-type="bibr" rid="B56-ijms-20-03317">56</xref>]. Interestingly, a de novo variant in a canonical splice site of <italic>LRP1</italic> has recently been identified in ASD patients [<xref ref-type="bibr" rid="B60-ijms-20-03317">60</xref>]. LRP1 is involved in several signaling pathways including cholesterol and lipid metabolism. Defects in this protein result in degeneration of dendritic spines and synapses and in neuroinflammation [<xref ref-type="bibr" rid="B100-ijms-20-03317">100</xref>]. These data suggest that genetic variants of <italic>LRP1</italic> exert their role in psychiatric diseases impairing more than one pathway. Similarly, other lipoprotein receptors from the same family, such as LRP2 and LRP8, have been implicated in autism and psychosis [<xref ref-type="bibr" rid="B60-ijms-20-03317">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-03317">61</xref>]. Taken together, these findings strongly suggest that alterations of MVA pathway and cholesterol metabolism are implicated in the pathogenesis of ASD, altering the availability and distribution of cholesterol and isoprenoids, both necessary for the proper brain function.</p>
</sec>
<sec id="sec5-ijms-20-03317">
<title>5. Rett Syndrome</title>
<p>Rett syndrome (RTT, OMIM #312750) is another disease without a direct link to cholesterol metabolism. However, several recent studies suggest a dysregulation of cholesterol metabolism. RTT. </p>
<p>RTT was first identified by the pediatric neurologist Andreas Rett, upon the observation of identical stereotypies in different female patients. The first examinations led the scientist to believe that symptomatology was primarily associated to metabolic defects: for this reason, this pathology was initially named cerebroatrophic hyperammonaemia in 1966 [<xref ref-type="bibr" rid="B62-ijms-20-03317">62</xref>]. Subsequently, the continuous growth of knowledge allowed to better characterize the disorder, which was officially accepted by the whole scientific community after 17 years from its discovery [<xref ref-type="bibr" rid="B63-ijms-20-03317">63</xref>]. RTT is a X-linked neurological disorder affecting only female with a prevalence of 1 out of 10,000 live births [<xref ref-type="bibr" rid="B64-ijms-20-03317">64</xref>]. The first neuronal symptoms appear at the age of 6–18 months. Their state worsens progressively leading to loss of previously acquired speech and motor skills, and the occurrence of stereotypic hand movements, irregular breathing, difficulties in walking and seizures [<xref ref-type="bibr" rid="B65-ijms-20-03317">65</xref>]. In 95% of the cases, RTT is caused by mutations in gene encoding for methyl CpG binding protein 2 (<italic>MECP2</italic>). This protein plays a key role in gene silencing through methylation-dependent remodeling of chromatin structure, and suppresses gene transcription through the association with several co-repressors [<xref ref-type="bibr" rid="B14-ijms-20-03317">14</xref>]. MeCP2 is ubiquitously present. At present, it is unclear, why and how defects in this protein impair neuronal functions. Its level of expression is particularly high in neurons suggesting that it contributes to the establishment and/or maintenance of neuronal maturation and plasticity [<xref ref-type="bibr" rid="B66-ijms-20-03317">66</xref>,<xref ref-type="bibr" rid="B67-ijms-20-03317">67</xref>]. Besides mutations in <italic>MECP2</italic> gene, some individuals develop atypical forms of RTT, which are associated with mutations in X-linked cyclin-dependent kinase-like 5 (<italic>CDKL5</italic>; OMIM #300203) or Forkhead box G1 (<italic>FOXG1</italic>; OMIM #164874). Furthermore, several RTT patients still harbor undefined mutations [<xref ref-type="bibr" rid="B67-ijms-20-03317">67</xref>]. Individuals affected by RTT display a decrease in brain volume and a concomitant reduction in head circumference [<xref ref-type="bibr" rid="B68-ijms-20-03317">68</xref>,<xref ref-type="bibr" rid="B69-ijms-20-03317">69</xref>], which are strongly associated to a smaller size of neurons and to an enhanced compaction of cells, particularly at the level of layers III and V of the cerebral cortex, substantia nigra, thalamus, cerebellum, basal ganglia, hippocampus and amygdala [<xref ref-type="bibr" rid="B70-ijms-20-03317">70</xref>]. Disruptions at neuronal level also involve a reduction in dendritic arborization [<xref ref-type="bibr" rid="B101-ijms-20-03317">101</xref>], and the dysfunction related to synapse physiology represent another hallmark of the disease [<xref ref-type="bibr" rid="B71-ijms-20-03317">71</xref>,<xref ref-type="bibr" rid="B76-ijms-20-03317">76</xref>]. It is becoming increasingly clear that RTT is deeply associated to important metabolic alterations [<xref ref-type="bibr" rid="B67-ijms-20-03317">67</xref>]. For instance, it has been observed that metabolic hormones such as leptin and adiponectin are increased in plasma derived from RTT patients [<xref ref-type="bibr" rid="B72-ijms-20-03317">72</xref>,<xref ref-type="bibr" rid="B73-ijms-20-03317">73</xref>], and abnormal carbohydrate metabolism is also present in cerebrospinal fluid of RTT individuals [<xref ref-type="bibr" rid="B74-ijms-20-03317">74</xref>]. In addition, recent evidence demonstrates that RTT physiopathology is associated to deregulations in cholesterol metabolism.</p>
<p>The first report linking RTT to cholesterol metabolism demonstrated enhanced levels of plasma total cholesterol, LDL (low density lipoprotein)-cholesterol and HDL (High density lipoprotein)-cholesterol in RTT patients, whereas no significant change was observed in the amount of total triglycerydes [<xref ref-type="bibr" rid="B102-ijms-20-03317">102</xref>], suggesting that dysbalance in plasma lipid profile is restricted to cholesterol metabolism. In addition, the authors reported a strong reduction of scavenger receptor class B type 1 (SR-B1) expression in fibroblasts derived from RTT patients. This protein mediates the uptake of cholesteryl esters from HDL and LDL particles [<xref ref-type="bibr" rid="B102-ijms-20-03317">102</xref>]. Few months after, an independent group showed significant dysregulated expression of genes involved in cholesterol biosynthesis, such as <italic>Hmgcr</italic> and Squalene Epoxidase (<italic>Sqle</italic>), in both brains and livers of <italic>Mecp2</italic>-null mice and a concurrent reduction of cholesterol precursors and a decrease of cholesterol biosynthesis in the brain [<xref ref-type="bibr" rid="B77-ijms-20-03317">77</xref>,<xref ref-type="bibr" rid="B78-ijms-20-03317">78</xref>,<xref ref-type="bibr" rid="B79-ijms-20-03317">79</xref>]. Alterations were also observed in the amount of serum cholesterol derived from <italic>Mecp2</italic>-null mice, which was significantly increased [<xref ref-type="bibr" rid="B77-ijms-20-03317">77</xref>]. A subsequent transcriptome/proteome analysis further corroborated these findings indicating perturbation of cholesterol homeostasis in the brain cortex of <italic>Mecp2</italic>-null mouse model of RTT [<xref ref-type="bibr" rid="B80-ijms-20-03317">80</xref>]. Recent studies provide evidence for and against mevalonate/cholesterol synthesis pathway as valid therapeutic target. Lovastatin significantly improved systemic lipid profile, ameliorated motor behaviors and increased lifespan of <italic>Mecp2</italic>-null mice [<xref ref-type="bibr" rid="B77-ijms-20-03317">77</xref>], whereas a second study performed on <italic>Mecp2</italic>-deficient mice with a different genetic background show no effect of lovastatin [<xref ref-type="bibr" rid="B81-ijms-20-03317">81</xref>]. These results suggest that so far unknown modifiers impact the efficacy of lovastatin treatment on brain functions. Our studies support an involvement of cholesterol metabolism in RTT patients harboring mutations in <italic>Mecp2</italic> gene [<xref ref-type="bibr" rid="B14-ijms-20-03317">14</xref>,<xref ref-type="bibr" rid="B75-ijms-20-03317">75</xref>]. In agreement with other preclinical and clinical data [<xref ref-type="bibr" rid="B77-ijms-20-03317">77</xref>,<xref ref-type="bibr" rid="B102-ijms-20-03317">102</xref>], we observed a significant increase of total cholesterol and LDL-cholesterol plasma levels, and a decrease of SR-B1 protein expression in primary fibroblasts derived from RTT patients [<xref ref-type="bibr" rid="B75-ijms-20-03317">75</xref>]. Importantly, we reported a dramatic reduction in the activity of HMGCR. This finding was intriguingly supported by the fact that cholesterol biosynthesis is reduced in the adult brains of a <italic>Mecp2</italic>-null mouse strain [<xref ref-type="bibr" rid="B77-ijms-20-03317">77</xref>,<xref ref-type="bibr" rid="B78-ijms-20-03317">78</xref>]. Together with the reduction in HMGCR activity, we highlighted a concurrent increase in the protein amount of HMGCR in RTT fibroblasts. Other studies indicated that <italic>Hmgcr</italic> transcripts are increased in the brains of 28-day-old, as well as in the livers of 3- and 8-weeks <italic>Mecp2</italic>-null mice [<xref ref-type="bibr" rid="B67-ijms-20-03317">67</xref>,<xref ref-type="bibr" rid="B77-ijms-20-03317">77</xref>]. A rise in LDLR expression was noted in RTT fibroblasts [<xref ref-type="bibr" rid="B75-ijms-20-03317">75</xref>]. These changes suggest that low intracellular cholesterol content, as a consequence of HMGCR activity suppression in RTT fibroblasts, induces the classic feedback mechanism with activation of SREBP2 and the increase of its transcriptional targets such as LDLR (LDL receptor) and HMGCR [<xref ref-type="bibr" rid="B23-ijms-20-03317">23</xref>,<xref ref-type="bibr" rid="B55-ijms-20-03317">55</xref>,<xref ref-type="bibr" rid="B103-ijms-20-03317">103</xref>,<xref ref-type="bibr" rid="B104-ijms-20-03317">104</xref>,<xref ref-type="bibr" rid="B105-ijms-20-03317">105</xref>,<xref ref-type="bibr" rid="B106-ijms-20-03317">106</xref>,<xref ref-type="bibr" rid="B107-ijms-20-03317">107</xref>]. Furthermore, LDLR increase is also promoted by the decrease in degradative events, as suggested by the fall in Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9, a protein involved in LDLR degradation) plasma levels in RTT individuals [<xref ref-type="bibr" rid="B75-ijms-20-03317">75</xref>]. The reduced MVA production could affect the other products of the biosynthetic pathway such as ubiquinone, dolichol and, most importantly prenylation. The putative aberrant content of these molecules could deeply affect cellular physiology, so further investigations are required to better understand their prospective involvement in this disease.</p>
</sec>
<sec id="sec6-ijms-20-03317" sec-type="conclusions">
<title>6. Conclusions and Outlook</title>
<p>The MVA/cholesterol pathway is crucial for CNS development and function and consequently, any dysfunction of this fundamental metabolic pathway is likely to provoke pathologic changes in the brain. Mutations in genes directly involved in MVA/cholesterol metabolism cause a range of diseases, many of which present neurologic and psychiatric symptoms (e.g. SLOS, NPC, desmosterolosis). This raises the question whether other diseases presenting similar symptoms are related albeit indirectly to the MVA/cholesterol pathway. </p>
<p>Up to now, there is no direct proof that ASD and RTT are caused by defects in MVA/cholesterol pathway. However, the available data clearly demand new studies to investigate the state of MVA/cholesterol homeostasis in RTT and ASD. This includes more efforts to clarify the reliability of experimental models, and to delve deeper into the role of cholesterol metabolism in this neurological disorders. For instance, it would be interesting to assess whether disruption in cholesterol biosynthesis occurs in atypical RTT patients harboring mutations on genes different from <italic>Mecp2</italic>. The analysis of different cholesterol precursors and metabolites in the cerebrospinal fluid of RTT patients could be useful in order to provide a more direct estimation of cholesterol metabolism in the brain. Moreover, it is imperative to study in a more general manner whether and how ASD and RTT imply changes in lipid metabolism including fatty acids and phospholipids. Overall, there are first hints that MVA/cholesterol pathway are affected in diseases such as ASD and RTT, but further studies are necessary to address causal links, to identify the underlying mechanisms and the specific brain cell types involved, and finally, to determine whether MVA/cholesterol metabolism is a potential pharmacological targets to treat these devastating diseases.</p>
</sec>
</body>
<back>
<notes>
<title>Funding</title>
<p>This research was funded by PRIN-MIUR, Contract grant number: 2015SHM58M_004 to VP - Departments of Excellence - 2017 - legge 232/2016 - art.1, commi 314–337 awarded to Dept. of Science - University Roma Tre - Rome - Italy for 2018–2022.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflicts of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">7-DHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">7-dehydrocholesterol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">24-S-OH</td>
<td align="left" colspan="1" rowspan="1" valign="top">24-<italic>S</italic> hydroxycholestero</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Alzheimer’s disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ASD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autism Spectrum Disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ABCA1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATP binding cassette 1 protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CNS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Central Nervous system</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CDKL5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cyclin-dependent kinase-like 5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CYP46A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cholesterol 24-hydroxylase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DHCR7</td>
<td align="left" colspan="1" rowspan="1" valign="top">17-Dehydrocholesterol reductase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ER</td>
<td align="left" colspan="1" rowspan="1" valign="top">Endoplasmic reticulum</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HDL</td>
<td align="left" colspan="1" rowspan="1" valign="top">High Density Lipoprotein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Huntington’s disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HMG-CoA</td>
<td align="left" colspan="1" rowspan="1" valign="top">3-hydroxy-3-methylglutaryl Coenzyme A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HMGCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">3-hydroxy-3-methylglutaryl Coenzyme A reductase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HTT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Huntingtin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LDL</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low density lipoprotein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LDLR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low density lipoprotein receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LRP1</td>
<td align="left" colspan="1" rowspan="1" valign="top">LDLR related protein </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">MeCP2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Methyl CpG binding protein 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">MVA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mevalonate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">NPC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Niemann-Pick type C </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PCSK9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Proprotein Convertase Subtilisin/Kexin type 9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RTT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rett syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SLOS</td>
<td align="left" colspan="1" rowspan="1" valign="top">Smith–Lemli–Opitz syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SQLE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Squalene epoxidase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SR-B1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Scavenger Receptor class B type 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SREBP2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sterol Regulatory Element Binding Protein 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">VPA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Valproic acid</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-20-03317">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dietschy</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Turley</surname>
<given-names>S.D.</given-names>
</name>
</person-group>
<article-title>Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal</article-title>
<source/>J. Lipid Res.
          <year>2004</year>
<volume>45</volume>
<fpage>1375</fpage>
<lpage>1397</lpage>
<pub-id pub-id-type="pmid">15254070</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-20-03317">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfrieger</surname>
<given-names>F.W.</given-names>
</name>
</person-group>
<article-title>Outsourcing in the brain: Do neurons depend on cholesterol delivery by astrocytes?</article-title>
<source/>Bioessays
          <year>2003</year>
<volume>25</volume>
<fpage>72</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1002/bies.10195</pub-id>
<pub-id pub-id-type="pmid">12508285</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-20-03317">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leboffe</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Trapani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Cholesterol homeostasis failure in the brain: Implications for synaptic dysfunction and cognitive decline</article-title>
<source/>Curr. Med. Chem.
          <year>2014</year>
<volume>21</volume>
<fpage>2788</fpage>
<lpage>2802</lpage>
<pub-id pub-id-type="doi">10.2174/0929867321666140303142902</pub-id>
<pub-id pub-id-type="pmid">24606521</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-20-03317">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mondal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mesmin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maxfield</surname>
<given-names>F.R.</given-names>
</name>
</person-group>
<article-title>Sterols are mainly in the cytoplasmic leaflet of the plasma membrane and the endocytic recycling compartment in CHO cells</article-title>
<source/>Mol. Biol. Cell
          <year>2009</year>
<volume>20</volume>
<fpage>581</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1091/mbc.e08-07-0785</pub-id>
<pub-id pub-id-type="pmid">19019985</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-20-03317">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Lipid rafts: A signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders</article-title>
<source/>Front. Behav. Neurosci.
          <year>2014</year>
<volume>8</volume>
<fpage>104</fpage>
<pub-id pub-id-type="doi">10.3389/fnbeh.2014.00104</pub-id>
<pub-id pub-id-type="pmid">24723866</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-20-03317">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Lipid rafts at postsynaptic sites: Distribution, function and linkage to postsynaptic density</article-title>
<source/>Neurosci. Res.
          <year>2002</year>
<volume>44</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/S0168-0102(02)00080-9</pub-id>
<pub-id pub-id-type="pmid">12204288</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-20-03317">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gil</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cubi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Blasi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Aguilera</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Synaptic proteins associate with a sub-set of lipid rafts when isolated from nerve endings at physiological temperature</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2006</year>
<volume>348</volume>
<fpage>1334</fpage>
<lpage>1342</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2006.07.201</pub-id>
<pub-id pub-id-type="pmid">16920068</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-20-03317">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Halverson-Tamboli</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Rasenick</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Lipid raft microdomains and neurotransmitter signalling</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2007</year>
<volume>8</volume>
<fpage>128</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2059</pub-id>
<pub-id pub-id-type="pmid">17195035</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-20-03317">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wasser</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Kavalali</surname>
<given-names>E.T.</given-names>
</name>
</person-group>
<article-title>Leaky synapses: Regulation of spontaneous neurotransmission in central synapses</article-title>
<source/>Neuroscience
          <year>2009</year>
<volume>158</volume>
<fpage>177</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.03.028</pub-id>
<pub-id pub-id-type="pmid">18434032</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-20-03317">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mailman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hariharan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karten</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol</article-title>
<source/>J. Neurochem.
          <year>2011</year>
<volume>119</volume>
<fpage>1002</fpage>
<lpage>1015</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07474.x</pub-id>
<pub-id pub-id-type="pmid">21899539</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-20-03317">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sooksawate</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Simmonds</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Effects of membrane cholesterol on the sensitivity of the GABA(A) receptor to GABA in acutely dissociated rat hippocampal neurones</article-title>
<source/>Neuropharmacology
          <year>2001</year>
<volume>40</volume>
<fpage>178</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1016/S0028-3908(00)00159-3</pub-id>
<pub-id pub-id-type="pmid">11114396</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-20-03317">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mauch</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Nagler</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schumacher</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goritz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pfrieger</surname>
<given-names>F.W.</given-names>
</name>
</person-group>
<article-title>CNS synaptogenesis promoted by glia-derived cholesterol</article-title>
<source/>Science
          <year>2001</year>
<volume>294</volume>
<fpage>1354</fpage>
<lpage>1357</lpage>
<pub-id pub-id-type="doi">10.1126/science.294.5545.1354</pub-id>
<pub-id pub-id-type="pmid">11701931</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-20-03317">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfrieger</surname>
<given-names>F.W.</given-names>
</name>
<name>
<surname>Ungerer</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Cholesterol metabolism in neurons and astrocytes</article-title>
<source/>Prog. Lipid. Res.
          <year>2011</year>
<volume>50</volume>
<fpage>357</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1016/j.plipres.2011.06.002</pub-id>
<pub-id pub-id-type="pmid">21741992</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-20-03317">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fracassi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marangoni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rosso</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fioramonti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Siteni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Statins and the Brain: More than Lipid Lowering Agents?</article-title>
<source/>Curr. Neuropharmacol.
          <year>2019</year>
<volume>17</volume>
<fpage>59</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.2174/1570159X15666170703101816</pub-id>
<pub-id pub-id-type="pmid">28676012</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-20-03317">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trapani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Hypercholesterolemia and 3-hydroxy 3-methylglutaryl Coenzyme A reductase regulation during ageing</article-title>
<source/>Sci. World J.
          <year>2009</year>
<volume>9</volume>
<fpage>564</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="doi">10.1100/tsw.2009.81</pub-id>
<pub-id pub-id-type="pmid">19578714</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-20-03317">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sever</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>DeBose-Boyd</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain</article-title>
<source/>Mol. Cell
          <year>2003</year>
<volume>11</volume>
<fpage>25</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/S1097-2765(02)00822-5</pub-id>
<pub-id pub-id-type="pmid">12535518</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-20-03317">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikonen</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Mechanisms for cellular cholesterol transport: Defects and human disease</article-title>
<source/>Physiol. Rev.
          <year>2006</year>
<volume>86</volume>
<fpage>1237</fpage>
<lpage>1261</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00022.2005</pub-id>
<pub-id pub-id-type="pmid">17015489</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-20-03317">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cartocci</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Servadio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Can Cholesterol Metabolism Modulation Affect Brain Function and Behavior?</article-title>
<source/>J. Cell Physiol.
          <year>2017</year>
<volume>232</volume>
<fpage>281</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.25488</pub-id>
<pub-id pub-id-type="pmid">27414240</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-20-03317">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leoni</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Caccia</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>24S-hydroxycholesterol in plasma: A marker of cholesterol turnover in neurodegenerative diseases</article-title>
<source/>Biochimie
          <year>2013</year>
<volume>95</volume>
<fpage>595</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="doi">10.1016/j.biochi.2012.09.025</pub-id>
<pub-id pub-id-type="pmid">23041502</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-20-03317">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boussicault</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lamaziere</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Planques</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heck</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Moumne</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Despres</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bolte</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pages</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease</article-title>
<source/>Brain
          <year>2016</year>
<volume>139</volume>
<fpage>953</fpage>
<lpage>970</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awv384</pub-id>
<pub-id pub-id-type="pmid">26912634</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-20-03317">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iuliano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Crick</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Zerbinati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tritapepe</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Abdel-Khalik</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Poirot</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>W.J.</given-names>
</name>
</person-group>
<article-title>Cholesterol metabolites exported from human brain</article-title>
<source/>Steroids
          <year>2015</year>
<volume>99</volume>
<fpage>189</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="doi">10.1016/j.steroids.2015.01.026</pub-id>
<pub-id pub-id-type="pmid">25668615</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-20-03317">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trapani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lecis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Regulation of cholesterol biosynthetic pathway in different regions of the rat central nervous system</article-title>
<source/>Acta. Physiol. (Oxf)
          <year>2012</year>
<volume>206</volume>
<fpage>62</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1111/j.1748-1716.2012.02450.x</pub-id>
<pub-id pub-id-type="pmid">22591135</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-20-03317">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trapani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Age- and sex-related differences in extra-hepatic low-density lipoprotein receptor</article-title>
<source/>J. Cell Physiol.
          <year>2011</year>
<volume>226</volume>
<fpage>2610</fpage>
<lpage>2616</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.22607</pub-id>
<pub-id pub-id-type="pmid">21792919</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-20-03317">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Pfrieger</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dotti</surname>
<given-names>C.G.</given-names>
</name>
</person-group>
<article-title>Cholesterol in brain disease: Sometimes determinant and frequently implicated</article-title>
<source/>EMBO. Rep.
          <year>2014</year>
<volume>15</volume>
<fpage>1036</fpage>
<lpage>1052</lpage>
<pub-id pub-id-type="doi">10.15252/embr.201439225</pub-id>
<pub-id pub-id-type="pmid">25223281</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-20-03317">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunniff</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kratz</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Natowicz</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>R.I.</given-names>
</name>
</person-group>
<article-title>Clinical and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism</article-title>
<source/>Am. J. Med. Genet.
          <year>1997</year>
<volume>68</volume>
<fpage>263</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19970131)68:3&lt;263::AID-AJMG4&gt;3.0.CO;2-N</pub-id>
<pub-id pub-id-type="pmid">9024557</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-20-03317">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porter</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Ekker</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>von Kessler</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Cotter</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Koonin</surname>
<given-names>E.V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hedgehog patterning activity: Role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain</article-title>
<source/>Cell
          <year>1996</year>
<volume>86</volume>
<fpage>21</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80074-4</pub-id>
<pub-id pub-id-type="pmid">8689684</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-20-03317">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Beachy</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Teratogen-mediated inhibition of target tissue response to Shh signaling</article-title>
<source/>Science
          <year>1998</year>
<volume>280</volume>
<fpage>1603</fpage>
<lpage>1607</lpage>
<pub-id pub-id-type="doi">10.1126/science.280.5369.1603</pub-id>
<pub-id pub-id-type="pmid">9616123</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-20-03317">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koide</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hayata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>K.W.</given-names>
</name>
</person-group>
<article-title>Negative regulation of Hedgehog signaling by the cholesterogenic enzyme 7-dehydrocholesterol reductase</article-title>
<source/>Development
          <year>2006</year>
<volume>133</volume>
<fpage>2395</fpage>
<lpage>2405</lpage>
<pub-id pub-id-type="doi">10.1242/dev.02393</pub-id>
<pub-id pub-id-type="pmid">16687448</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-20-03317">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeBarber</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Eroglu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Merkens</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Pappu</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>Smith-Lemli-Opitz syndrome</article-title>
<source/>Expert. Rev. Mol. Med.
          <year>2011</year>
<volume>13</volume>
<fpage>e24</fpage>
<pub-id pub-id-type="doi">10.1017/S146239941100189X</pub-id>
<pub-id pub-id-type="pmid">21777499</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-20-03317">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wassif</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>F.D.</given-names>
</name>
<name>
<surname>Javitt</surname>
<given-names>N.B.</given-names>
</name>
</person-group>
<article-title>27-Hydroxylation of 7- and 8-dehydrocholesterol in Smith-Lemli-Opitz syndrome: A novel metabolic pathway</article-title>
<source/>Steroids
          <year>2003</year>
<volume>68</volume>
<fpage>497</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1016/S0039-128X(03)00090-4</pub-id>
<pub-id pub-id-type="pmid">12906934</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-20-03317">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elias</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Irons</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Hurley</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Tint</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Salen</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS)</article-title>
<source/>Am. J. Med. Genet.
          <year>1997</year>
<volume>68</volume>
<fpage>305</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19970131)68:3&lt;305::AID-AJMG11&gt;3.0.CO;2-X</pub-id>
<pub-id pub-id-type="pmid">9024564</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-20-03317">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nwokoro</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Mulvihill</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome</article-title>
<source/>Am. J. Med. Genet.
          <year>1997</year>
<volume>68</volume>
<fpage>315</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19970131)68:3&lt;315::AID-AJMG13&gt;3.0.CO;2-W</pub-id>
<pub-id pub-id-type="pmid">9024566</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-20-03317">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Donnai</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Winter</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Burn</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Smith-Lemli-Opitz syndrome: A variable clinical and biochemical phenotype</article-title>
<source/>J. Med. Genet.
          <year>1998</year>
<volume>35</volume>
<fpage>558</fpage>
<lpage>565</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.35.7.558</pub-id>
<pub-id pub-id-type="pmid">9678700</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-20-03317">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szabo</surname>
<given-names>G.P.</given-names>
</name>
<name>
<surname>Olah</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Kozak</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Balogh</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Blahakova</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Olah</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>A patient with Smith-Lemli-Opitz syndrome: Novel mutation of the DHCR7 gene and effects of therapy with simvastatin and cholesterol supplement</article-title>
<source/>Eur. J. Pediatr.
          <year>2010</year>
<volume>169</volume>
<fpage>121</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1007/s00431-009-0987-z</pub-id>
<pub-id pub-id-type="pmid">19365639</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-20-03317">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fliesler</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Oxysterols and Retinal Degeneration in a Rat Model of Smith-Lemli-Opitz Syndrome: Implications for an Improved Therapeutic Intervention</article-title>
<source/>Molecules
          <year>2018</year>
<volume>23</volume>
<!--<pub-id pub-id-type="pii">E2720</pub-id>-->
<pub-id pub-id-type="doi">10.3390/molecules23102720</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-20-03317">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanier</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Millat</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Niemann-Pick disease type C</article-title>
<source/>Clin. Genet.
          <year>2003</year>
<volume>64</volume>
<fpage>269</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1034/j.1399-0004.2003.00147.x</pub-id>
<pub-id pub-id-type="pmid">12974729</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-20-03317">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sevin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lesca</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Millat</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lyon-Caen</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Vanier</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Sedel</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>The adult form of Niemann-Pick disease type C</article-title>
<source/>Brain
          <year>2007</year>
<volume>130</volume>
<fpage>120</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awl260</pub-id>
<pub-id pub-id-type="pmid">17003072</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-20-03317">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walterfang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fietz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abel</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bowman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mocellin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Velakoulis</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Gender dimorphism in siblings with schizophrenia-like psychosis due to Niemann-Pick disease type C</article-title>
<source/>J. Inherit. Metab. Dis.
          <year>2009</year>
<volume>32</volume>
<issue>Suppl. 1</issue>
<fpage>S221</fpage>
<lpage>S226</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-009-1173-1</pub-id>
<pub-id pub-id-type="pmid">19609713</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-20-03317">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Probert</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ruiz-Rodado</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>te Vruchte</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Claridge</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Edgar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tocchio</surname>
<given-names>A.Z.</given-names>
</name>
<name>
<surname>Lachmann</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Grootveld</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Urinary excretion and metabolism of miglustat and valproate in patients with Niemann-Pick type C1 disease: One- and two-dimensional solution-state (1)H NMR studies</article-title>
<source/>J. Pharm. Biomed. Anal.
          <year>2016</year>
<volume>117</volume>
<fpage>276</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpba.2015.08.011</pub-id>
<pub-id pub-id-type="pmid">26397207</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-20-03317">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vite</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Bagel</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Swain</surname>
<given-names>G.P.</given-names>
</name>
<name>
<surname>Prociuk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sikora</surname>
<given-names>T.U.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ruane</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Crooks</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease</article-title>
<source/>Sci. Transl. Med.
          <year>2015</year>
<volume>7</volume>
<fpage>276ra26</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3010101</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-20-03317">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demais</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Barthelemy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Perraut</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ungerer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Keime</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reibel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pfrieger</surname>
<given-names>F.W.</given-names>
</name>
</person-group>
<article-title>Reversal of Pathologic Lipid Accumulation in NPC1-Deficient Neurons by Drug-Promoted Release of LAMP1-Coated Lamellar Inclusions</article-title>
<source/>J. Neurosci.
          <year>2016</year>
<volume>36</volume>
<fpage>8012</fpage>
<lpage>8025</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0900-16.2016</pub-id>
<pub-id pub-id-type="pmid">27466344</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-20-03317">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zerenturk</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Sharpe</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Ikonen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Desmosterol and DHCR24: Unexpected new directions for a terminal step in cholesterol synthesis</article-title>
<source/>Prog. Lipid. Res.
          <year>2013</year>
<volume>52</volume>
<fpage>666</fpage>
<lpage>680</lpage>
<pub-id pub-id-type="doi">10.1016/j.plipres.2013.09.002</pub-id>
<pub-id pub-id-type="pmid">24095826</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-20-03317">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Mace</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Maeda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schmechel</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology</article-title>
<source/>Neurobiol. Dis.
          <year>2005</year>
<volume>18</volume>
<fpage>390</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2004.10.013</pub-id>
<pub-id pub-id-type="pmid">15686968</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-20-03317">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desai</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>DeKosky</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Kamboh</surname>
<given-names>M.I.</given-names>
</name>
</person-group>
<article-title>Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer’s disease</article-title>
<source/>Neurosci. Lett.
          <year>2002</year>
<volume>328</volume>
<fpage>9</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(02)00443-3</pub-id>
<pub-id pub-id-type="pmid">12123847</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-20-03317">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolsch</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lutjohann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ludwig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ptok</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Jessen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>von Bergmann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Heun</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer’s disease</article-title>
<source/>Mol. Psychiatry
          <year>2002</year>
<volume>7</volume>
<fpage>899</fpage>
<lpage>902</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001109</pub-id>
<pub-id pub-id-type="pmid">12232784</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-20-03317">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wollmer</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Streffer</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Lutjohann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tsolaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iakovidou</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hegi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pasch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Bergmann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nitsch</surname>
<given-names>R.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer’s disease</article-title>
<source/>Neurobiol. Aging
          <year>2003</year>
<volume>24</volume>
<fpage>421</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="doi">10.1016/S0197-4580(02)00094-5</pub-id>
<pub-id pub-id-type="pmid">12600718</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-20-03317">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burton</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Papworth</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Haig</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McCowan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Stott</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>T.J.</given-names>
</name>
</person-group>
<article-title>Statin Use is Not Associated with Future Long-Term Care Admission: Extended Follow-Up of Two Randomised Controlled Trials</article-title>
<source/>Drugs Aging
          <year>2018</year>
<volume>35</volume>
<fpage>657</fpage>
<lpage>663</lpage>
<pub-id pub-id-type="doi">10.1007/s40266-018-0560-4</pub-id>
<pub-id pub-id-type="pmid">29916140</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-20-03317">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shakour</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bianconi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pirro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Barreto</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Hadizadeh</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sahebkar</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>In silico evidence of direct interaction between statins and beta-amyloid</article-title>
<source/>J. Cell Biochem.
          <year>2019</year>
<volume>120</volume>
<fpage>4710</fpage>
<lpage>4715</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.27761</pub-id>
<pub-id pub-id-type="pmid">30260016</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-20-03317">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trettel</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rigamonti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hilditch-Maguire</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Persichetti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cattaneo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells</article-title>
<source/>Hum. Mol. Genet.
          <year>2000</year>
<volume>9</volume>
<fpage>2799</fpage>
<lpage>2809</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/9.19.2799</pub-id>
<pub-id pub-id-type="pmid">11092756</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-20-03317">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sipione</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rigamonti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Valenza</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zuccato</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pritchard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kooperberg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Cattaneo</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses</article-title>
<source/>Hum. Mol. Genet.
          <year>2002</year>
<volume>11</volume>
<fpage>1953</fpage>
<lpage>1965</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/11.17.1953</pub-id>
<pub-id pub-id-type="pmid">12165557</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-20-03317">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenza</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marullo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Paolo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cesana</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zuccato</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Biella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cattaneo</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington’s disease</article-title>
<source/>Cell Death Differ.
          <year>2015</year>
<volume>22</volume>
<fpage>690</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2014.162</pub-id>
<pub-id pub-id-type="pmid">25301063</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-20-03317">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shankaran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Paolo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Leoni</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Caccia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ferrari Bardile</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mohammed</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Di Donato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marchionini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington’s disease: A cross-validation study in Q175 knock-in mice</article-title>
<source/>Neurobiol. Dis.
          <year>2017</year>
<volume>98</volume>
<fpage>66</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2016.11.013</pub-id>
<pub-id pub-id-type="pmid">27913290</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-20-03317">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valenza</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Di Paolo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ruozi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Belletti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ferrari Bardile</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Leoni</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Caccia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brilli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Di Donato</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington’s disease mice</article-title>
<source/>EMBO. Mol. Med.
          <year>2015</year>
<volume>7</volume>
<fpage>1547</fpage>
<lpage>1564</lpage>
<pub-id pub-id-type="doi">10.15252/emmm.201505413</pub-id>
<pub-id pub-id-type="pmid">26589247</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-20-03317">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servadio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vanderschuren</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Modeling autism-relevant behavioral phenotypes in rats and mice: Do ‘autistic’ rodents exist?</article-title>
<source/>Behav. Pharmacol.
          <year>2015</year>
<volume>26</volume>
<fpage>522</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.1097/FBP.0000000000000163</pub-id>
<pub-id pub-id-type="pmid">26226143</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-20-03317">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cartocci</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Catallo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tempestilli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pfrieger</surname>
<given-names>F.W.</given-names>
</name>
<name>
<surname>Bronzuoli</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Scuderi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Servadio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Altered Brain Cholesterol/Isoprenoid Metabolism in a Rat Model of Autism Spectrum Disorders</article-title>
<source/>Neuroscience
          <year>2018</year>
<volume>372</volume>
<fpage>27</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.12.053</pub-id>
<pub-id pub-id-type="pmid">29309878</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-20-03317">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cartocci</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tonini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Di Pippo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vuono</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schiavi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Prenatal exposure to valproate induces sex-, age-, and tissue-dependent alterations of cholesterol metabolism: Potential implications on autism</article-title>
<source/>J. Cell Physiol.
          <year>2019</year>
<volume>234</volume>
<fpage>4362</fpage>
<lpage>4374</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.27218</pub-id>
<pub-id pub-id-type="pmid">30341891</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-20-03317">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melancia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Schiavi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Servadio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cartocci</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Campolongo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Palmery</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling</article-title>
<source/>Br. J. Pharmacol.
          <year>2018</year>
<volume>175</volume>
<fpage>3699</fpage>
<lpage>3712</lpage>
<pub-id pub-id-type="doi">10.1111/bph.14435</pub-id>
<pub-id pub-id-type="pmid">29968249</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-20-03317">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Autism</article-title>
<source/>Lancet
          <year>2014</year>
<volume>383</volume>
<fpage>896</fpage>
<lpage>910</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)61539-1</pub-id>
<pub-id pub-id-type="pmid">24074734</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-20-03317">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Regier</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Kuhl</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Kupfer</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>The DSM-5: Classification and criteria changes</article-title>
<source/>World Psychiatry
          <year>2013</year>
<volume>12</volume>
<fpage>92</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1002/wps.20050</pub-id>
<pub-id pub-id-type="pmid">23737408</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-20-03317">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torrico</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Mosca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vivo-Luque</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hervas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fernandez-Castillo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Aloy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bayes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fullerton</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Cormand</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Truncating variant burden in high-functioning autism and pleiotropic effects of LRP1 across psychiatric phenotypes</article-title>
<source/>J. Psychiatry Neurosci.
          <year>2019</year>
<volume>44</volume>
<fpage>1</fpage>
<lpage>10</lpage>
</element-citation>
</ref>
<ref id="B61-ijms-20-03317">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ionita-Laza</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Makarov</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Scan-statistic approach identifies clusters of rare disease variants in LRP2, a gene linked and associated with autism spectrum disorders, in three datasets</article-title>
<source/>Am. J. Hum. Genet.
          <year>2012</year>
<volume>90</volume>
<fpage>1002</fpage>
<lpage>1013</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2012.04.010</pub-id>
<pub-id pub-id-type="pmid">22578327</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-20-03317">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rett</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>On a unusual brain atrophy syndrome in hyperammonemia in childhood</article-title>
<source/>Wien. Med. Wochenschr.
          <year>1966</year>
<volume>116</volume>
<fpage>723</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="pmid">5300597</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-20-03317">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagberg</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Aicardi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: Report of 35 cases</article-title>
<source/>Ann. Neurol.
          <year>1983</year>
<volume>14</volume>
<fpage>471</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410140412</pub-id>
<pub-id pub-id-type="pmid">6638958</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-20-03317">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patankar</surname>
<given-names>J.V.</given-names>
</name>
</person-group>
<article-title>Cholesterol metabolism is a potential therapeutic target for Rett syndrome</article-title>
<source/>Clin. Genet.
          <year>2014</year>
<volume>85</volume>
<fpage>229</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="doi">10.1111/cge.12284</pub-id>
<pub-id pub-id-type="pmid">24102619</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-20-03317">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chahrour</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>MeCP2, a key contributor to neurological disease, activates and represses transcription</article-title>
<source/>Science
          <year>2008</year>
<volume>320</volume>
<fpage>1224</fpage>
<lpage>1229</lpage>
<pub-id pub-id-type="doi">10.1126/science.1153252</pub-id>
<pub-id pub-id-type="pmid">18511691</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-20-03317">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Jugloff</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Logan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eubanks</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells</article-title>
<source/>J. Neurobiol.
          <year>2003</year>
<volume>55</volume>
<fpage>86</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1002/neu.10201</pub-id>
<pub-id pub-id-type="pmid">12605461</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-20-03317">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kyle</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Vashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Justice</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Rett syndrome: A neurological disorder with metabolic components</article-title>
<source/>Open Biol.
          <year>2018</year>
<volume>8</volume>
<pub-id pub-id-type="doi">10.1098/rsob.170216</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-20-03317">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jellinger</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Seitelberger</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Neuropathology of Rett syndrome</article-title>
<source/>Am. J. Med. Genet. Suppl.
          <year>1986</year>
<volume>1</volume>
<fpage>259</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320250528</pub-id>
<pub-id pub-id-type="pmid">3087188</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-20-03317">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jellinger</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Percy</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>Neuropathology of Rett syndrome</article-title>
<source/>Acta. Neuropathol.
          <year>1988</year>
<volume>76</volume>
<fpage>142</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1007/BF00688098</pub-id>
<pub-id pub-id-type="pmid">2900587</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-20-03317">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>The neuropathology of the Rett syndrome</article-title>
<source/>Brain Dev.
          <year>1992</year>
<volume>14</volume>
<fpage>S89</fpage>
<lpage>S98</lpage>
<pub-id pub-id-type="pmid">1626639</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-20-03317">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoghbi</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>E.O.</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Glaze</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Percy</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid biogenic amines and biopterin in Rett syndrome</article-title>
<source/>Ann. Neurol.
          <year>1989</year>
<volume>25</volume>
<fpage>56</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1002/ana.410250109</pub-id>
<pub-id pub-id-type="pmid">2913929</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-20-03317">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acampa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guideri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Blardi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>De Lalla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zappella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Auteri</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Sympathetic overactivity and plasma leptin levels in Rett syndrome</article-title>
<source/>Neurosci. Lett.
          <year>2008</year>
<volume>432</volume>
<fpage>69</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2007.12.030</pub-id>
<pub-id pub-id-type="pmid">18226448</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-20-03317">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blardi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>De Lalla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>D’Ambrogio</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vonella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ceccatelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Auteri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Long-term plasma levels of leptin and adiponectin in Rett syndrome</article-title>
<source/>Clin. Endocrinol. (Oxf)
          <year>2009</year>
<volume>70</volume>
<fpage>706</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2265.2008.03386.x</pub-id>
<pub-id pub-id-type="pmid">18710461</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-20-03317">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Urabe</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Percy</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Komori</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Ohtani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kuriya</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Abnormal carbohydrate metabolism in cerebrospinal fluid in Rett syndrome</article-title>
<source/>J. Child. Neurol.
          <year>1994</year>
<volume>9</volume>
<fpage>26</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1177/088307389400900105</pub-id>
<pub-id pub-id-type="pmid">8151077</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-20-03317">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trapani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Di Tunno</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sticozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Cholesterol metabolism is altered in Rett syndrome: A study on plasma and primary cultured fibroblasts derived from patients</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e104834</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0104834</pub-id>
<pub-id pub-id-type="pmid">25118178</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-20-03317">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taneja</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ogier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brooks-Harris</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>S.B.</given-names>
</name>
</person-group>
<article-title>Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome</article-title>
<source/>J. Neurosci.
          <year>2009</year>
<volume>29</volume>
<fpage>12187</fpage>
<lpage>12195</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3156-09.2009</pub-id>
<pub-id pub-id-type="pmid">19793977</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-20-03317">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchovecky</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Turley</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Kyle</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pieper</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>D.W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome</article-title>
<source/>Nat. Genet.
          <year>2013</year>
<volume>45</volume>
<fpage>1013</fpage>
<lpage>1020</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2714</pub-id>
<pub-id pub-id-type="pmid">23892605</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-20-03317">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Posey</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Turley</surname>
<given-names>S.D.</given-names>
</name>
</person-group>
<article-title>Suppression of brain cholesterol synthesis in male Mecp2-deficient mice is age dependent and not accompanied by a concurrent change in the rate of fatty acid synthesis</article-title>
<source/>Brain Res.
          <year>2017</year>
<volume>1654</volume>
<fpage>77</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2016.10.021</pub-id>
<pub-id pub-id-type="pmid">27789278</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-20-03317">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lutjohann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Kerksiek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Turley</surname>
<given-names>S.D.</given-names>
</name>
</person-group>
<article-title>Identification of Correlative Shifts in Indices of Brain Cholesterol Metabolism in the C57BL6/Mecp2(tm1.1Bird) Mouse, a Model for Rett Syndrome</article-title>
<source/>Lipids
          <year>2018</year>
<volume>53</volume>
<fpage>363</fpage>
<lpage>373</lpage>
<pub-id pub-id-type="doi">10.1002/lipd.12041</pub-id>
<pub-id pub-id-type="pmid">29770459</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-20-03317">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacheco</surname>
<given-names>N.L.</given-names>
</name>
<name>
<surname>Heaven</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Holt</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Crossman</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Boggio</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>RNA sequencing and proteomics approaches reveal novel deficits in the cortex of Mecp2-deficient mice, a model for Rett syndrome</article-title>
<source/>Mol. Autism.
          <year>2017</year>
<volume>8</volume>
<fpage>56</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-017-0174-4</pub-id>
<pub-id pub-id-type="pmid">29090078</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-20-03317">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sacchetti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bagnati</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Passoni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fusco</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Carli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Invernizzi</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice</article-title>
<source/>Elife
          <year>2016</year>
<volume>5</volume>
<fpage>e22409</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.22409</pub-id>
<pub-id pub-id-type="pmid">27892851</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-20-03317">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golomb</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism</article-title>
<source/>Am. J. Cardiovasc. Drugs
          <year>2008</year>
<volume>8</volume>
<fpage>373</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="doi">10.2165/0129784-200808060-00004</pub-id>
<pub-id pub-id-type="pmid">19159124</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-20-03317">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jose</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Anandkumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Narmadha</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Sandeep</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>A comparative effect of atorvastatin with other statins in patients of hyperlipidemia</article-title>
<source/>Indian J. Pharmacol.
          <year>2012</year>
<volume>44</volume>
<fpage>261</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="doi">10.4103/0253-7613.93864</pub-id>
<pub-id pub-id-type="pmid">22529488</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-20-03317">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reilly</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cham</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Golomb</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>First-degree relatives with behavioural adverse effects on statins</article-title>
<source/>BMJ. Case Rep.
          <year>2011</year>
<volume>2011</volume>
<pub-id pub-id-type="doi">10.1136/bcr.09.2011.4758</pub-id>
<pub-id pub-id-type="pmid">22675104</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-20-03317">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Seguin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Therrien</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Riopel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chawky</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lesage</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Turecki</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Familial aggregation of suicidal behavior: A family study of male suicide completers from the general population</article-title>
<source/>Am. J. Psychiatry
          <year>2005</year>
<volume>162</volume>
<fpage>1017</fpage>
<lpage>1019</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.162.5.1017</pub-id>
<pub-id pub-id-type="pmid">15863812</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-20-03317">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruljancic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mihanovic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cepelak</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Thrombocyte serotonin and serum cholesterol concentration in suicidal and non-suicidal depressed patients</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2011</year>
<volume>35</volume>
<fpage>1261</fpage>
<lpage>1267</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2011.02.007</pub-id>
<pub-id pub-id-type="pmid">21338651</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-20-03317">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Berardis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Serroni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Campanella</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Olivieri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moschetta</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Martinotti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Di Giannantonio</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Safety and efficacy of combined clozapine-azathioprine treatment in a case of resistant schizophrenia associated with Behcet’s disease: A 2-year follow-up</article-title>
<source/>Gen. Hosp. Psychiatry
          <year>2012</year>
<volume>35</volume>
<fpage>213.e9</fpage>
<lpage>213.e11</lpage>
<pub-id pub-id-type="doi">10.1016/j.genhosppsych.2012.06.007</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-20-03317">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tedders</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Fokong</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Wesley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Low cholesterol is associated with depression among US household population</article-title>
<source/>J. Affect. Disord.
          <year>2011</year>
<volume>135</volume>
<fpage>115</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2011.06.045</pub-id>
<pub-id pub-id-type="pmid">21802743</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-20-03317">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papakostas</surname>
<given-names>G.I.</given-names>
</name>
<name>
<surname>Perlis</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Scalia</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Fava</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2006</year>
<volume>26</volume>
<fpage>56</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1097/01.jcp.0000195042.62724.76</pub-id>
<pub-id pub-id-type="pmid">16415707</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-20-03317">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wysokinski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Strzelecki</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kloszewska</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder</article-title>
<source/>Diabetes Metab. Syndr.
          <year>2015</year>
<volume>9</volume>
<fpage>168</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1016/j.dsx.2015.04.004</pub-id>
<pub-id pub-id-type="pmid">25943411</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-20-03317">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nadeau</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Larue</surname>
<given-names>G.H.</given-names>
</name>
</person-group>
<article-title>Blood Cholesterol in Schizophrenia</article-title>
<source/>Can. Med. Assoc. J.
          <year>1952</year>
<volume>66</volume>
<fpage>320</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="pmid">14916369</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-20-03317">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goff</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>McEvoy</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Nasrallah</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Daumit</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Lamberti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D’Agostino</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Stroup</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls</article-title>
<source/>Schizophr. Res.
          <year>2005</year>
<volume>80</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2005.08.010</pub-id>
<pub-id pub-id-type="pmid">16198088</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-20-03317">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jow</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia</article-title>
<source/>J. Affect. Disord.
          <year>2006</year>
<volume>90</volume>
<fpage>21</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2005.09.015</pub-id>
<pub-id pub-id-type="pmid">16324751</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-20-03317">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zachor</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Recommendations for early diagnosis and intervention in autism spectrum disorders: An Italian-Israeli consensus conference</article-title>
<source/>Eur. J. Paediatr. Neurol.
          <year>2014</year>
<volume>18</volume>
<fpage>107</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2013.09.002</pub-id>
<pub-id pub-id-type="pmid">24095105</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-20-03317">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeste</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Disentangling the heterogeneity of autism spectrum disorder through genetic findings</article-title>
<source/>Nat. Rev. Neurol.
          <year>2014</year>
<volume>10</volume>
<fpage>74</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1038/nrneurol.2013.278</pub-id>
<pub-id pub-id-type="pmid">24468882</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-20-03317">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaste</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Leboyer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Autism risk factors: Genes, environment, and gene-environment interactions</article-title>
<source/>Dialogues Clin. Neurosci.
          <year>2012</year>
<volume>14</volume>
<fpage>281</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="pmid">23226953</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-20-03317">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiCicco-Bloom</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zwaigenbaum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Courchesne</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dager</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>L.J.</given-names>
</name>
</person-group>
<article-title>The developmental neurobiology of autism spectrum disorder</article-title>
<source/>J. Neurosci.
          <year>2006</year>
<volume>26</volume>
<fpage>6897</fpage>
<lpage>6906</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1712-06.2006</pub-id>
<pub-id pub-id-type="pmid">16807320</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-20-03317">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loomes</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hull</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mandy</surname>
<given-names>W.P.L.</given-names>
</name>
</person-group>
<article-title>What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis</article-title>
<source/>J. Am. Acad. Child. Adolesc. Psychiatry
          <year>2017</year>
<volume>56</volume>
<fpage>466</fpage>
<lpage>474</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaac.2017.03.013</pub-id>
<pub-id pub-id-type="pmid">28545751</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-20-03317">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Marinis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Trentalance</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Sex differences in hepatic regulation of cholesterol homeostasis</article-title>
<source/>J. Endocrinol.
          <year>2008</year>
<volume>198</volume>
<fpage>635</fpage>
<lpage>643</lpage>
<pub-id pub-id-type="doi">10.1677/JOE-08-0242</pub-id>
<pub-id pub-id-type="pmid">18603607</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-20-03317">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Trotter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Weeber</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration</article-title>
<source/>J. Neurosci.
          <year>2010</year>
<volume>30</volume>
<fpage>17068</fpage>
<lpage>17078</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4067-10.2010</pub-id>
<pub-id pub-id-type="pmid">21159977</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-20-03317">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufmann</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>H.W.</given-names>
</name>
</person-group>
<article-title>Dendritic anomalies in disorders associated with mental retardation</article-title>
<source/>Cereb. Cortex.
          <year>2000</year>
<volume>10</volume>
<fpage>981</fpage>
<lpage>991</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/10.10.981</pub-id>
<pub-id pub-id-type="pmid">11007549</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-20-03317">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sticozzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Belmonte</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pecorelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cervellati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Leoncini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Signorini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ciccoli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Felice</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hayek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Valacchi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Scavenger receptor B1 post-translational modifications in Rett syndrome</article-title>
<source/>FEBS. Lett.
          <year>2013</year>
<volume>587</volume>
<fpage>2199</fpage>
<lpage>2204</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2013.05.042</pub-id>
<pub-id pub-id-type="pmid">23711372</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-20-03317">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trapani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Melli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Campolongo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Swiezewska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pucillo</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fanelli</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions</article-title>
<source/>FASEB J.
          <year>2011</year>
<volume>25</volume>
<fpage>4037</fpage>
<lpage>4047</lpage>
<pub-id pub-id-type="doi">10.1096/fj.11-184218</pub-id>
<pub-id pub-id-type="pmid">21798954</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-20-03317">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cartocci</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Tunno</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pfrieger</surname>
<given-names>F.W.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Modulation of the Isoprenoid/Cholesterol Biosynthetic Pathway During Neuronal Differentiation In Vitro</article-title>
<source/>J. Cell Biochem.
          <year>2016</year>
<volume>117</volume>
<fpage>2036</fpage>
<lpage>2044</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.25500</pub-id>
<pub-id pub-id-type="pmid">27392312</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-20-03317">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Giovanni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Analysis of the protein network of cholesterol homeostasis in different brain regions: An age and sex dependent perspective</article-title>
<source/>J. Cell Physiol.
          <year>2013</year>
<volume>228</volume>
<fpage>1561</fpage>
<lpage>1567</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.24315</pub-id>
<pub-id pub-id-type="pmid">23280554</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-20-03317">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Manduca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lecis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rosso</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Swiezewska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Simvastatin treatment highlights a new role for the isoprenoid/cholesterol biosynthetic pathway in the modulation of emotional reactivity and cognitive performance in rats</article-title>
<source/>Neuropsychopharmacology
          <year>2014</year>
<volume>39</volume>
<fpage>841</fpage>
<lpage>854</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2013.284</pub-id>
<pub-id pub-id-type="pmid">24108067</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-20-03317">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trapani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Segatto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pallottini</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?</article-title>
<source/>World J. Hepatol.
          <year>2013</year>
<volume>5</volume>
<fpage>676</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="doi">10.4254/wjh.v5.i12.676</pub-id>
<pub-id pub-id-type="pmid">24432184</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-20-03317-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Schematic representation of MVA pathway. Enzymes involved or potentially involved in neurologic and psychiatric diseases are highlighted in blue circles. Autism spectrum disorder (ASD), 3-hydroxy-3-methylglutaryl Coenzyme A reductase (HMGCR); 7-dehydrocholesterol reductase (DHCR7); 24-dehydrocholesterol reductase (DHCR24), Rett syndrome (RTT); Squalene Epoxidase (SQLE); Smith–Lemli–Opitz syndrome (SLOS). Dotted arrows represent multiple enzymatic reactions. ? represents the hypothetic involvement of the indicated enzyme in the onset of the disease.</p>
</caption>
<graphic xlink:href="ijms-20-03317-g001"></graphic>
</fig>
<table-wrap id="ijms-20-03317-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-03317-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Highlights of the direct and indirect involvement of MVA pathway in some brain diseases and the experimental models used. Smith–Lemli–Opitz syndrome (SLOS); NPC (Niemann-Pick type C); Alzheimer’s disease (AD); Huntington’s disease (HD); Autism spectrum disorder (ASD); Rett syndrome (RTT); 7-dehydrocholesterol reductase (<italic>DHCR7</italic>); 24-dehydrocholesterol reductase (<italic>DHCR24</italic>).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Disease</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Direct/Indirect Involvement of MVA Pathway</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Experimental Model</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">SLOS</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Direct <italic>DHCR7</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B24-ijms-20-03317">24</xref>,<xref ref-type="bibr" rid="B25-ijms-20-03317">25</xref>,<xref ref-type="bibr" rid="B26-ijms-20-03317">26</xref>,<xref ref-type="bibr" rid="B27-ijms-20-03317">27</xref>,<xref ref-type="bibr" rid="B28-ijms-20-03317">28</xref>,<xref ref-type="bibr" rid="B29-ijms-20-03317">29</xref>,<xref ref-type="bibr" rid="B30-ijms-20-03317">30</xref>,<xref ref-type="bibr" rid="B31-ijms-20-03317">31</xref>,<xref ref-type="bibr" rid="B32-ijms-20-03317">32</xref>,<xref ref-type="bibr" rid="B33-ijms-20-03317">33</xref>,<xref ref-type="bibr" rid="B34-ijms-20-03317">34</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rodents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B35-ijms-20-03317">35</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">NPC</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Direct <italic>NPC1</italic> or/and <italic>NPC2</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B36-ijms-20-03317">36</xref>,<xref ref-type="bibr" rid="B37-ijms-20-03317">37</xref>,<xref ref-type="bibr" rid="B38-ijms-20-03317">38</xref>,<xref ref-type="bibr" rid="B39-ijms-20-03317">39</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rodents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B40-ijms-20-03317">40</xref>,<xref ref-type="bibr" rid="B41-ijms-20-03317">41</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Desmosterolosis</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Direct <italic>DHCR24</italic></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B42-ijms-20-03317">42</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">AD</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Indirect</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rodents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B43-ijms-20-03317">43</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B44-ijms-20-03317">44</xref>,<xref ref-type="bibr" rid="B45-ijms-20-03317">45</xref>,<xref ref-type="bibr" rid="B46-ijms-20-03317">46</xref>,<xref ref-type="bibr" rid="B47-ijms-20-03317">47</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Silico</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B48-ijms-20-03317">48</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">HD</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Indirect</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Striatal mouse cell line</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B49-ijms-20-03317">49</xref>,<xref ref-type="bibr" rid="B50-ijms-20-03317">50</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rodents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B20-ijms-20-03317">20</xref>,<xref ref-type="bibr" rid="B51-ijms-20-03317">51</xref>,<xref ref-type="bibr" rid="B52-ijms-20-03317">52</xref>,<xref ref-type="bibr" rid="B53-ijms-20-03317">53</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Indirect</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rodents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B54-ijms-20-03317">54</xref>,<xref ref-type="bibr" rid="B55-ijms-20-03317">55</xref>,<xref ref-type="bibr" rid="B56-ijms-20-03317">56</xref>,<xref ref-type="bibr" rid="B57-ijms-20-03317">57</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B58-ijms-20-03317">58</xref>,<xref ref-type="bibr" rid="B59-ijms-20-03317">59</xref>,<xref ref-type="bibr" rid="B60-ijms-20-03317">60</xref>,<xref ref-type="bibr" rid="B61-ijms-20-03317">61</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">RTT</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">Indirect</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Human</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B62-ijms-20-03317">62</xref>,<xref ref-type="bibr" rid="B63-ijms-20-03317">63</xref>,<xref ref-type="bibr" rid="B64-ijms-20-03317">64</xref>,<xref ref-type="bibr" rid="B65-ijms-20-03317">65</xref>,<xref ref-type="bibr" rid="B66-ijms-20-03317">66</xref>,<xref ref-type="bibr" rid="B67-ijms-20-03317">67</xref>,<xref ref-type="bibr" rid="B68-ijms-20-03317">68</xref>,<xref ref-type="bibr" rid="B69-ijms-20-03317">69</xref>,<xref ref-type="bibr" rid="B70-ijms-20-03317">70</xref>,<xref ref-type="bibr" rid="B71-ijms-20-03317">71</xref>,<xref ref-type="bibr" rid="B72-ijms-20-03317">72</xref>,<xref ref-type="bibr" rid="B73-ijms-20-03317">73</xref>,<xref ref-type="bibr" rid="B74-ijms-20-03317">74</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Primary human fibroblasts </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B67-ijms-20-03317">67</xref>,<xref ref-type="bibr" rid="B75-ijms-20-03317">75</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Rodents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B76-ijms-20-03317">76</xref>,<xref ref-type="bibr" rid="B77-ijms-20-03317">77</xref>,<xref ref-type="bibr" rid="B78-ijms-20-03317">78</xref>,<xref ref-type="bibr" rid="B79-ijms-20-03317">79</xref>,<xref ref-type="bibr" rid="B80-ijms-20-03317">80</xref>,<xref ref-type="bibr" rid="B81-ijms-20-03317">81</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>